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Abstract
Background: The risk factors for progression of chronic kidney disease (CKD) in type 2 diabetes
mellitus (DM) have not been fully elucidated. Although uncontrolled blood pressure (BP) is known
to be deleterious, other factors may become more important once BP is treated.
Methods: All patients seen in the outpatient clinics of our hospital between January 1993 and
September 2002 with type 2 DM and clinical evidence of CKD were evaluated. Progression of
kidney disease was evaluated by rate of decline of glomerular filtration rate (GFR) as estimated
from the simplified MDRD formula. Variables associated with progression in univariate analyses
were examined by multivariate analysis to determine the factors independently associated with
kidney disease progression.
Results: 343 patients (mean age 69 years; all male; 77% Caucasian) were studied. Mean BP, glycated
hemoglobin, and serum cholesterol during the study period were 138/72 mmHg, 8.1%, and 4.8
mmol/L, respectively. Mean decline of GFR was 4.5 ml min-1 1.73 m2-1 yr-1 (range -14 to +32).
Low initial serum albumin (p < 0.001), black race (p < 0.001), and degree of proteinuria (p = 0.002),
but not blood pressure, glycated hemoglobin, or serum cholesterol, were independently associated
with progression.
Conclusion: In a cohort of diabetic patients with CKD in whom mean BP was < 140/80 mmHg,
the potentially remediable factors hypoalbuminemia and proteinuria but not blood pressure were
independently associated with progression of kidney disease. Further understanding of the
relationship between these factors and kidney disease progression may lead to beneficial therapies
in such patients.
Background
Diabetic nephropathy is the most common cause of end-
stage kidney disease (ESKD) in the United States and
worldwide. Most diabetic patients with ESKD have type 2
diabetes. Since only a minority of type 2 diabetic patients
develop kidney disease, predisposing factors for develop-
ment of the disease are operative. In addition, once clini-
cal kidney disease is evident, the rate of decline of
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glomerular filtration rate (GFR) is highly variable, ranging
from 2 to 20 ml min-1 yr-1 [1]. The reasons for these dif-
ferences in the rate of disease progression are multifacto-
rial, including both non-modifiable and modifiable
factors [2,3]. Blood pressure control is known to be
important in preventing adverse cardiovascular and renal
outcomes in diabetic patients with hypertension [4].
However, it is not clear whether or not blood pressure is
an important predictor of GFR decline in diabetic patients
with CKD in whom blood pressure is controlled.
The purpose of the present study was to determine the fac-
tors independently associated with chronic kidney disease
(CKD) progression assessed by rate of decline of GFR in a
cohort of male predominantly elderly veteran patients
with type 2 diabetes. In this population, in whom BP was
generally well controlled, hypoalbuminemia, black race,
and degree of proteinuria, but not blood pressure, were
associated with disease progression.
Methods
Subjects
A search of the computerized patient record system at
Hines VA Medical Center, Hines, Illinois was performed
to find all patients seen in the outpatient clinics between
January 1993 and September 2002 with type 2 DM and
clinical evidence of CKD. Potential subjects were included
if they had all of the following: a) type 2 DM [clinical
diagnosis and/or glycated hemoglobin > 6.5%]; b)
chronic kidney insufficiency, defined by a persistent eleva-
tion of serum creatinine (SCr) level; at least 3 serum creat-
inine values of > 124 µmol/L with at least a six-month
interval between the first and last serum creatinine value
were required for inclusion; c) proteinuria [positive urine
dipstick or urine protein > 0.15 g/d or urine albumin/cre-
atinine ratio ≥  30 mg/g]. GFR was calculated using the
simplified MDRD formula [GFR (ml min-1 1.73 m2-1) =
186 × (SCr)-1.154 × (age)-0.203 × (0.742 if female) × (1.210
if black)][5]. The serum creatinine concentration was not
calibrated to MDRD laboratory creatinine values. Patients
known to have another cause of kidney disease (e.g., poly-
cystic kidney disease, ischemic nephropathy, or biopsy-
proven non-diabetic kidney disease) were excluded. In
order to determine rate of CKD progression, individual
GFR values were calculated from every serum creatinine
value between the time when the serum creatinine was
first noted to be > 124 µmol/L (baseline value) and either
the time of the last available serum creatinine or the com-
mencement of kidney replacement therapy. The rate of
GFR decline (slope) (ml min-1 1.73 m2-1 yr-1) for each
patient during the study period was then determined by
linear regression analysis using all calculated GFR values.
Decline in GFR was represented as a positive value. The
mean duration of the study period was 36 months (range
7–149). The mean number of GFR values utilized for
slope determination was 14 (range 3–69).
Co-variates
Information on age, race, weight, height, use of angi-
otensin converting enzyme (ACE) inhibitors or angi-
otensin receptor blockers (ARBs), blood pressure, glycated
hemoglobin, serum cholesterol, hemoglobin, serum albu-
min, and urine protein excretion was obtained from the
computerized patient record system. Age, weight (kg) and
height (m) were defined as the recorded values at the time
of the first laboratory creatinine measurement > 124
µmol/L. Body mass index (BMI) (kg/m2) was then calcu-
lated using the weight and height values. Race was self-
reported. Blood pressure was measured at each clinic visit
by a medical technician or a nurse (generally every 3–6
months) in the seated position using a mercury sphyg-
momanometer. Glycated hemoglobin was measured by
high performance liquid chromatography. Hemoglobin
values were measured by Coulter counter. Serum values of
creatinine, cholesterol, and albumin were measured by
automated analyzer. Urinary protein was measured by the
pyrogallol red-molybdate method and urinary albumin
by immunoturbidemetry. The degree of proteinuria was
classified as mild, moderate, or heavy. Mild proteinuria
was defined as dipstick trace-0.3 g/L and/or protein 0.15–
0.5 g/d and/or spot urine albumin/creatinine ratio of 30–
300 mg/g; moderate proteinuria was defined as dipstick
1.0 g/L and/or protein 0.5–3.0 g/d and/or spot urine albu-
min/creatinine ratio of 300–2000 mg/g; and heavy pro-
teinuria was defined as dipstick 3.0 g/L and/or protein >
3.0 g/d and/or spot urine albumin/creatinine ratio of >
2000 mg/g.
Statistical analysis
Mean values of systolic blood pressure, diastolic blood
pressure, glycated hemoglobin, and serum cholesterol
during the study period were computed for each patient
and utilized for analysis. Because degree of proteinuria
was a categorical variable, maximum degree of proteinu-
ria recorded during the study period was utilized. Since
hemoglobin and serum albumin values were expected to
decline as kidney disease progressed (see Discussion), ini-
tial hemoglobin and serum albumin values (i.e., values
obtained closest in time to the beginning of the study
period for each patient) were used. Univariate analyses
were performed using t-test for continuous variables and
Chi-square analysis for categorical variables. Multivariate
linear regression analyses using rate of decline (slope) of
GFR as the dependent variable were then performed in
both age-adjusted and non-age-adjusted fashion using an
automated backwards elimination procedure to delete
factors with a P-value > 0.15 from the model one at a time.
Multivariate analyses were performed using all variablesBMC Nephrology 2005, 6:8 http://www.biomedcentral.com/1471-2369/6/8
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as well as using only those variables found to be signifi-
cantly associated with progression on univariate analysis.
Data are expressed as mean ± SD. All P values were two
sided and a P value of <0.05 was used to indicate statistical
significance. Statistical analyses were performed using
Systat software (SPSS, Chicago, IL).
This study complied with the recommendations of the
Declaration of Helsinki and was approved by the local
Institutional Review Board.
Results
Demographic and clinical variables in the 343 patients
who met study criteria are given in Table 1. The mean
study period was 36 months (range 7–149). The mean age
was 69 (range 43–92) with 73% of patients aged 65 or
older. The majority of patients (77%) were Caucasian.
Mean values for blood pressure, glycated hemoglobin,
and serum cholesterol during the study period were 138/
72 mmHg, 8.1%, and 4.8 mmol/L, respectively. The
majority of patients (71%) were treated with ACE
inhibitors or ARBs.
Mean rate of decline of GFR during the study period was
4.5 ml min-1 1.73 m2-1 yr-1 (range -14 to +32). The vari-
ables most highly associated with progression on univari-
ate analysis were lower initial serum albumin and greater
degree of proteinuria (p < 0.001), followed by younger
age and black race (p = 0.002), higher glycated hemo-
globin (p = 0.007), higher mean diastolic blood pressure
(p = 0.012), lower initial hemoglobin (p = 0.014), and
higher systolic blood pressure (p = 0.048) (Table 2). Fig-
ures 1 and 2 depict the association between decline in
GFR and degree of proteinuria and serum albumin levels,
respectively. Patients with greater degrees of proteinuria
not unexpectedly had higher rates of disease progression.
In addition, the most rapid disease progression was seen
in patients with the most profound hypoalbuminemia
(serum albumin level < 25 g/L). Rate of progression was
only approximately 3 ml min-1 1.73 m2-1 yr-1 with no
relationship between serum albumin and progression
once serum albumin levels were > 35 g/L. 138 patients
(40%) had systolic hypertension (BP = 140 mmHg systo-
lic). There was no association between systolic blood pres-
sure and GFR decline when systolic BP was < 140 mmHg.
However, above that level, rate of GFR decline increased
with increasing systolic BP (Figure 3). Only 49 patients
(14%) had diastolic BP readings of = 80 mmHg. The rela-
tionship between diastolic BP and GFR decline was U-
shaped, with the lowest rate of progression in the 75–79
mmHg range (Figure 4).
The following independent variables were considered for
selection in the stepwise linear regression, using back-
wards selection: age, race, systolic BP, diastolic BP,
Table 1: Demographic and clinical variables in 343 study patients
Age (years) 69 ± 9 (43–92)
Race 80 black; 263 Caucasian
Body mass index (kg/m2) 30 ± 5 (16–50)
Initial serum creatinine (µmol/L) 150 ± 35 (124–389)
Initial GFR (ml/min/1.73 m2) 10 (13–77)
Degree of proteinuria (see text) Group 1= 118; Group 2 = 100; Group 3 = 125
Mean systolic blood pressure (mmHg) 138 ± 14 (96–189)
Mean diastolic blood pressure (mmHg) 72 ± 8 (49–97)
Treatment with ACEI/ARB No = 99; Yes = 244
Mean serum cholesterol (mmol/L) 4.8 ± 1.0 (2.3–8.9)
Mean glycated hemoglobin (%) 8.1 ± 1.6 (5.5–17)
Initial hemoglobin (g/L) 128 ± 19 (67–179)
Initial serum albumin (g/L) 34 ± 6 (17–53)
Table 2: Univariate association of demographic and clinical 
variables with decline in GFR
Variable r p
Age -0.192 0.002
Race * 0.002
Body mass index -0.010 0.859
Initial serum creatinine -0.137 0.055
Degree of proteinuria * <0.001
Mean systolic blood pressure 0.107 0.048
Mean diastolic blood pressure 0.136 0.012
Treatment with ACEI/ARB 0.039 0.482
Mean serum cholesterol 0.014 0.797
Mean glycated hemoglobin 0.147 0.007
Initial hemoglobin -0.136 0.014
Initial serum albumin -0.295 <0.001
*categorical independent variablesBMC Nephrology 2005, 6:8 http://www.biomedcentral.com/1471-2369/6/8
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glycated hemoglobin, degree of proteinuria, initial hemo-
globin, and initial serum albumin level. Because of the U-
shaped relationship between diastolic BP and GFR
decline, (diastolic BP)2 was also evaluated. When both
diastolic BP and (diastolic BP)2 were entered into the
regression equation, neither was significantly associated
with BP decline (p = 0.943 for diastolic BP and p = 0.935
for (diastolic BP)2). In addition, systolic blood pressure
and glycated hemoglobin were not independently associ-
ated with progression in this analysis. Lower initial serum
albumin, black race, and degree of proteinuria were the
only variables independently associated with progression
at the p < 0.05 level (Table 3). Similar results were seen
using a non-age-adjusted model (Table 3) and when all
variables regardless of their association with progression
were entered into the regression equations.
As regression diagnostics for data from two of the patients
indicated high leverage and one was an outlier (with a
Studentized residual of 5.071) in the linear regression
model, further analyses were performed excluding these
cases. The results were not changed after exclusion of
these cases, with initial serum albumin (p = 0.001), pro-
teinuria (p = 0.002) and black race (p = 0.003) the only
significant variables independently associated with GFR
decline.
Discussion
The most important finding of this study is that the poten-
tially modifiable factors hypoalbuminemia and proteinu-
ria were strongly and independently associated with
kidney disease progression in a mostly elderly male type 2
diabetic population with generally well-controlled blood
Relationship between degree of proteinuria and rate of GFR decline (1 = mild proteinuria; 2 = moderate proteinuria; 3= heavy  proteinuria; see text for definitions) Figure 1
Relationship between degree of proteinuria and rate of GFR decline (1 = mild proteinuria; 2 = moderate proteinuria; 3= heavy 
proteinuria; see text for definitions)
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pressure. As shown in Figure 4, there was no effect of
systolic BP on progression with systolic BPs < 140 mmHg,
and diastolic BP had a U-shaped relationship with GFR
decline (Figure 4). Therefore systolic BP and both diasto-
lic BP and (diastolic BP)2 were examined in the multivar-
iate regression analyses. In these analyses, there was no
independent association between systolic BP or either
diastolic BP or (diastolic BP)2 and rate of GFR decline in
this population.
Blood pressure control is known to be important in pre-
venting adverse cardiovascular and renal outcomes in dia-
betic patients [4]. However, prospective interventional
studies demonstrating slowing of kidney disease progres-
sion by blood pressure control were mostly performed in
type 1 diabetic patients in whom blood pressure was gen-
erally poorly controlled by current standards [6-12] (see
Table 4). More recent studies in type 1 and type 2 diabetic
patients designed to evaluate the effects of blood pressure
control on progression have found lesser effects, either
because they were underpowered [13] or possibly because
of lower pre-treatment and on-treatment blood pressures
[14,15]. In support of the latter possibility, in the Reduc-
tion of Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan (RENAAL) trial, proteinuria,
increased serum creatinine, hypoalbuminemia, and ane-
mia at baseline but not baseline blood pressure were pre-
dictors of progression [16]. In a recent analysis of RENAAL
data, last systolic (but not diastolic) BP prior to end points
predicted a higher risk for progressive nephropathy; how-
ever, this effect was only seen when systolic BP was > 140
mmHg [17]. In a multivariate analysis of data from the
Relationship between initial serum albumin level and rate of GFR decline Figure 2
Relationship between initial serum albumin level and rate of GFR decline.
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Irbesartan Diabetic Nephropathy Trial (IDNT), another
large clinical trial in type 2 diabetic patients, hypoalbu-
minemia, increased serum creatinine, albuminuria,
decreased hemoglobin, and increased blood pressure
were predictors in that order of importance [18]. In the
ramipril trial of Lewis et al. there was no significant differ-
ence in rate of decline in GFR between two groups of type
1 diabetics with mean arterial blood pressures of 98 vs. 92
mmHg, respectively [14]. Similarly, in the ABCD trial, a
type 2 diabetes trial, there was no benefit of decreasing
diastolic blood pressure from 80–89 mmHg to 75 mmHg
(difference in actual BPs 138/86 vs. 132/78, or mean arte-
rial blood pressures of 103 vs. 96 mmHg) [15].
A recent observational study from Japan investigated fac-
tors affecting progression of kidney failure in type 2
diabetic patients [2]. These investigators found that lack of
insulin therapy, hypoalbuminemia, higher mean blood
pressure, and lower hemoglobin at baseline were inde-
pendent predictors of kidney failure. However, this study
involved only 85 patients and a relatively short survey
time (14 months), and disease progression was assessed
by time to doubling of serum creatinine. Moreover, the
mean arterial blood pressure at baseline was 105 mmHg,
which is higher than that seen in most recent studies
(mean blood pressures during the survey period were not
given). In a larger analysis of 227 Caucasian patients with
diabetic nephropathy from the Steno Diabetes Center in
Denmark, in whom the mean follow-up time was 6.5
years, rate of decline of GFR was predicted by higher val-
ues of baseline and mean albuminuria, systolic blood
pressure, hemoglobin A1c, and degree of diabetic retinop-
athy, as well as by baseline GFR, age, lower hemoglobin
values, and smoking status during follow-up [3]. In this
study, two-thirds of the patients had mean systolic BPs
during follow-up of > 149 mmHg. In contrast, in our
observational study, the mean BP was 138/72 mmHg
(mean arterial blood pressure 94 mmHg) during the study
Relationship between mean systolic blood pressure during the study period and rate of GFR decline Figure 3
Relationship between mean systolic blood pressure during the study period and rate of GFR decline.
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(follow-up) period. This level of BP control was substan-
tially better than that achieved in the Danish study and
was also better than that obtained (i.e., 146/76 mmHg) in
a recent clinical trial in which a stepped-care algorithm
designed to meet American Diabetes Association blood
pressure goals of < 130/80 was employed [19]. Thus,
taken together, the findings of interventional and observa-
tional studies suggest that BP control becomes less impor-
tant in delaying progression when BP is not very elevated.
The results of our study indicate that hypoalbuminemia
independently predicted GFR decline. In a study investi-
gating the relationship between blood pressure and dia-
betic kidney disease progression, Dillon [20] found that
mean serum albumin was associated with decline in GFR.
However, since serum albumin could decrease as kidney
disease progresses as a consequence of anorexia and mal-
nutrition, this association could be attributed to reverse
causality. Using a similar approach to that employed in
Relationship between mean diastolic blood pressure during the study period and rate of GFR decline Figure 4
Relationship between mean diastolic blood pressure during the study period and rate of GFR decline.
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Table 3: Variables independently associated with rate of GFR 
decline in multivariate linear regression models
Age-adjusted:
Variable F ratio P value
Initial serum albumin 14.5 <0.001
Black race 13.2 <0.001
Degree of proteinuria 10.2 0.002
Non-age-adjusted:
Variable F ratio P value
Initial serum albumin 15.6 <0.001
Black race 14.4 <0.001
Degree of proteinuria 12.8 <0.001BMC Nephrology 2005, 6:8 http://www.biomedcentral.com/1471-2369/6/8
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Table 4: Summary of Interventional Studies in Diabetic Patients Examining Effect of Blood Pressure Control on Kidney Disease 
Progression
AUTHOR STUDY POPULATION STUDY SIZE/ DURATION RESULTS
Mogensen et al. Br Med J 1982 [6] Type I DM
Mean BP 162/103
Urinary albumin 3.9 g/d
GFR 86 ml min-1 1.73 m2-1
N = 5
73 month treatment period 
compared to previous 20–31 
month untreated period
BP decreased to 144/95 mmHg 
with treatment
Rate of decline of GFR decreased 
from 14.8 to 5.9 ml min-1 yr-1 in 
treated period
Parving et al. Lancet 1983 [7] Type I DM
Mean BP 144/97 mmHg
Proteinuria > 0.5 g/d
GFR approx 77 ml min-1 1.73 m2-1
N = 10
39 month treatment period 
compared to 29 month untreated 
period
BP decreased to 128/84 mmHg 
with treatment
Rate of decline of GFR decreased 
from 0.9 to 0.39 ml min-1 mo-1 in 
treated period
Bjorck et al. Br Med J 1986 [8] Type I DM
Mean BP 163/97 mmHg
Mean proteinuria 2.9 g/d
Mean serum Cr 2.1
N = 14
4.8 yrs (2.8 yrs untreated followed 
by 2 yrs treated with captopril)
BP decreased to 155/94 mmHg 
with treatment (p < 0.02)
Urinary protein decreased from 
2.9 to 2.8 (NS)
Rate of decline of GFR decreased 
from 10.3 to 5.5 ml min-1 yr-1 (p < 
0.02)
Parving et al. Br Med J 1987 [9] Type I DM
> 200 ug/min albuminuria
BP 143/96 mmHg pre-treatment 
Mean GFR approx. 103 ml min-1 
1.73 m2-1
N = 11
32 mo. untreated followed by 6 yrs 
treated)
BP decreased to 129/84 mmHg 
with treatment (p < 0.01)
Albuminuria decreased from 1038 
to 504 ug/min (p < 0.01)
Rate of decline of GFR decreased 
from 0.89 to 0.22 ml-1 min-1 mo-1 
during treatment (p < 0.01)
Parving et al. BMJ 1988 [10] Type I DM treated with captopril 
or placebo
> 0.3 g/d albumin (mean approx. 
0.95)
Baseline BP 146/93 mmHg and 
137/95 mmHg in 2 groups, 
respectively
Serum Cr < 120 µmol/L
GFR mean approx. 97 ml min-1 
1.73 m2-1
N = 31
Captopril (N = 18) Control (N = 
13)
2.5 yrs
MAP decreased by 8.7 mmHg to 
136/85 by captopril; increased by 
6.6 mmHg to 145/98 mmHg in 
controls (p < 0.001) Albumin 
excretion decreased to 390 ug/min 
in captopril, increased to 1367 ug/
min in controls (p < 0.001)
GFR decline 5.8 ml min-1 yr-1 in 
captopril vs. 10 ml min-1 yr-1 in 
controls (p < 0.01)
Sawicki et al J Diabetes 
Complications 1995 [11]
Type I DM
Proteinuria > 0.5 g/d
Serum Cr < 265 µmol/L
Diabetic retinopathy
BP > 140/90 mmHg or need for BP 
meds
Intensive treatment including BP 
self-monitoring with goal BP < 
140/90 mmHg (IT) vs. routine 
treatment (RT)
N ~ 100
5 yrs
Primary study endpoints (need for 
dialysis or death) decreased in IT 
group
UKPDS 38 1998 13 Type II DM
Serum Cr < 177 µmol/L
BP <150/85 mmHg vs. < 180/105 
mmHg
N = 31 with overt nephropathy (> 
300 mg/l albuminuria) 8.4 yrs
Insufficient numbers to determine 
if BP control benefitted patients 
with overt nephropathy (P = 0.06)
Trocha et al. J Hypertension 1999 
[12]
Type I DM
Proteinuria > 0.5 g/d
Cr < 265 µmol/L
Diabetic retinopathy
BP > 140/90 mmHg or need for BP 
meds
BP self-monitoring with goal BP < 
140/90 (IT) vs. routine care (RT)
N = 91
IT (N = 45)
RT (N = 46)
10 yrs
Primary study endpoints (need for 
dialysis or death) decreased in IT 
group
Lewis et al. Am J Kidney Dis 1999 
[14]
Type I DM with overt nephropathy
Serum Cr < 354 µmol/L
MAP of 92 mmHg (Group I) vs. 
102–107 mmHg (Group II)
N = 129
N = 63 in Group I
N = 66 in Group II
2 yrs
MAP 92 mmHg in Group I vs. 98 in 
Group II
No significant difference in rate of 
decline of GFR
Significant decrease in albuminuria 
in intensive groupBMC Nephrology 2005, 6:8 http://www.biomedcentral.com/1471-2369/6/8
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our study, Ueda et al. [2] reported that baseline serum
albumin was a predictor of the development of ESKD in
Japanese patients with type 2 diabetes. This study used
reciprocal creatinine and/or the development of ESKD as
endpoints rather than GFR decline; moreover, the popula-
tion was quite different from the predominantly Cauca-
sian U.S. male veterans examined in our study.
Nevertheless, these data, in conjunction with the RENAAL
and IDNT data, in which hypoalbuminemia was also an
independent predictor of progression in type 2 diabetes,
support the relationship between hypoalbuminemia and
GFR decline.
Why would hypoalbuminemia be predictive of kidney
disease progression? One possibility is that the serum
albumin level reflects the degree of proteinuria, a known
risk factor for progression in most kidney diseases, includ-
ing diabetes [3,21-27]. However, this is not the sole expla-
nation for the association between serum albumin level
and disease progression, because hypoalbuminemia is
significantly associated with GFR decline after adjustment
for the effects of proteinuria. Since many patients with
CKD have evidence of chronic inflammation, as reflected
by elevated C-reactive protein (CRP) levels, anemia of
chronic disease, and elevated D-dimer and vonWillebrand
factor levels [28-30], it is possible that hypoalbuminemia
may reflect an inflammatory state, which may increase
kidney disease progression [30], possibly by causing oxi-
dative stress [31]. In addition, decreased GFR may result
in accumulation of proinflammatory compounds (such
as advanced glycated end-products and oxidation prod-
ucts) with resultant hypoalbuminemia [32] and kidney
injury [33]. The hypothesis that low serum albumin
reflects an inflammatory state, which contributes to pro-
gression of kidney disease is supported by recent studies
in both non-diabetic [34,35] and diabetic [36]
populations.
As has been done by other investigators [2,16,18], we uti-
lized initial serum albumin levels in our analyses rather
than mean values during the treatment period. Of note,
when mean serum albumin values were utilized, there
was also a strong association between serum albumin and
decline in GFR (data not shown). However, we believed
that this could be due to a "reverse" association, as pro-
gression of renal failure could result in decreased protein
intake, malnutrition, and a decrease in serum albumin
level. We also chose to use initial values for hemoglobin
rather than mean values during the treatment period. This
was done because of the well known direct association
between anemia and lower GFR due to erythropoietin
deficiency. Mean values of other continuous variables
(such as blood pressure) were utilized in order to better
capture treatment effects during the observation period
and to enhance the precision of the analysis by utilizing
many measurements of each variable.
We included patients who had the diagnosis of diabetes
mellitus and/or mean glycated hemoglobin values > 6.5%
in our analysis. We did not utilize blood glucose values for
study inclusion or for analysis since it was not always pos-
sible to determine if a sample was a fasting or random
sample. We did not find an association between blood
glucose control (as reflected by glycated hemoglobin) and
progression in our study. The role of hyperglycemia in
progression of nephropathy in type 2 diabetes is not clear,
in large part because many studies have lacked statistical
power. However, in post-hoc analyses of two large clinical
trials, RENAAL [16] and IDNT [18], baseline glycated
hemoglobin was not an important predictor. However, in
their observational study, Rossing et al. [3] recently
reported that mean glycated hemoglobin was associated
with GFR decline. The lack of association between serum
cholesterol and progression in our study is consistent with
these other studies [3,16,18].
The observational nature of our study does have limita-
tions. For instance, there was no control over the type of
medication used for hypertension, nor any control over
diabetes management or dietary intake. We utilized a for-
mula to estimate rate of GFR decline instead of perform-
ing direct clearance measurements. The formula utilized,
Estacio et al. Diabetes Care 2000 
[15]
Type II DM
DBP > 90 mmHg
CCr of 76 ml min-1 1.73 m2-1 
Randomized to intensive therapy 
(IT) (DBP < 75 mmHg) or 
moderate therapy (MT) (DBP 80–
89 mmHg)
N = 470 total
N = 83 with overt proteinuria
5 yrs
BP decreased significantly with IT 
vs. MT (132/78 mmHg vs. 138/86 
mmHg)
Pts with overt albuminuria 
demonstrated a steady decline in 
creatinine clearance of 5–6 ml min-
1 1.73 m2-1 yr-1 throughout the 
follow-up period in both IT and 
MT groups (pNS)
*categorical independent variables
Table 4: Summary of Interventional Studies in Diabetic Patients Examining Effect of Blood Pressure Control on Kidney Disease 
Progression (Continued)BMC Nephrology 2005, 6:8 http://www.biomedcentral.com/1471-2369/6/8
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namely the four-variable MDRD estimate, was developed
from a largely non-diabetic patient population. Moreover,
this formula loses accuracy when the GFR is > 60 ml min-
1 1.73 m2-1 and/or if the serum creatinine concentration
is not calibrated to MDRD laboratory creatinine values
[37]. However, our analysis is based on rate of decline of
GFR (slope analysis) and not absolute values of GFR and
most patients had baseline GFR values of < 60 ml min-1
1.73 m2-1. Moreover, the National Kidney Foundation
currently recommends using this prediction equation to
calculate GFR and monitor progression of kidney disease
[5]. Indeed, using rate of GFR decline as our outcome var-
iable has advantages over the doubling of serum creati-
nine utilized in many prospective clinical trials. This is
because doubling of serum creatinine reflects a
progressively smaller absolute GFR decline as the serum
creatinine increases. Finally, the nature of the kidney dis-
ease in our mostly elderly diabetic patients probably rep-
resented a mix of diabetic glomerulosclerosis,
hypertensive nephrosclerosis, and, in some cases, possibly
undiagnosed ischemic nephropathy, either alone or in
combination. We did not analyze data on retinopathy
since it was not always available in our computerized
database. We also did not analyze the relationship
between kidney disease progression and cardiovascular
disease. Despite these limitations, we believe that our
findings are relevant to usual clinical practice.
Conclusion
The results of our study may have important clinical
implications. Although blood pressure control is undeni-
ably important in delaying progression of kidney disease
in hypertensive diabetic patients, attention to other
potentially remediable factors may be more important in
delaying progression once BP is effectively treated. Anti-
proteinuric agents (such as ACE inhibitors and ARBs) may
exert beneficial actions beyond those due to BP control. In
addition, the finding that hypoalbuminemia is independ-
ently associated with progression of CKD due to type 2
diabetes after adjustment for the effects of proteinuria sug-
gests the possibility that inflammation (and/or
malnutrition) may be a progression promoter. In particu-
lar, further understanding of the role of inflammation in
CKD may lead to therapies which favorably affect kidney
disease progression in type 2 diabetic patients.
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